All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-12-05.
From the record
Arrowhead Pharmaceuticals, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2023-12-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+34.5% a year over 10 filed years; profitable in 2 of 10.
From the record
Arrowhead Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $31 million in fiscal 2017 to $451 million in fiscal 2026, up 34.5% a year; it rose in 4 of 9 years; the deepest fall was 99% from fiscal 2022 to fiscal 2024; net income was positive in 2 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Arrowhead Pharmaceuticals, Inc.'s shareholder treatment is put at 6.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 36% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -1420%: lost 1420¢ per shareholder dollar. Leverage 97%: owes 97¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-09-30, Arrowhead Pharmaceuticals, Inc. lost about 1420 cents for every dollar of shareholders' money. Leverage: it owed about 97 cents per dollar of assets, and net share issuance: its share count grew 5.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 35% of 315 in its family; net margin -159.1%.
From the record
Arrowhead Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $451 million in fiscal 2026 ranks in the top 20% by size; a net margin of -159.1% ranks in the top 50%; revenue growth of 23.3% a year over the last 3 filed years ranks in the top 35% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 36% of 315 in its family for leadership; chief executive since 2008.
From the record
Arrowhead Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Anzalone, Christopher Richard (Chief Executive Officer, as filed), filing under that title since 2008-01-24, 18.8 years (top 4% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 39%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 43% of 273 in its family for room to expand.
From the record
Arrowhead Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $63 million against no long-term debt tagged leaves 3.6% of its assets as net cash, bottom 18% of its family; cash from operations less capital spending is -63% of revenue (top 47%); research spending of 164% of revenue (top 44%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 37% of 306 in its family for growth drivers.
From the record
Arrowhead Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 23.3% a year over the last three filed years against 34.5% over all 10, slowing (bottom 32% of its family); the newest year grew -45.7% (bottom 18%); research spending grew 27.9% a year (top 16%); capital spending grew -59.2% a year (bottom 14%) (its annual reports). Arrowhead Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 38% of 233 in its family for expectations against reality.
From the record
Arrowhead Pharmaceuticals, Inc.'s newest year against its own record: revenue of $451 million in fiscal 2026 came in 70.7% below the $1.5 billion its prior three years' pace pointed to (bottom 12% of its family); net income of $717 million against a prior three-year average of $263 million (bottom 9%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 9%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made